1-1 of 1
on behalf of the StiL
Close
Save search
Sort by
Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Free
Mathias J. Rummel, U. von Gruenhagen, N. Niederle, F. Rothmann, H. Ballo, E. Weidmann, M. Welslau, G. Heil, H. Duerk, M. Stauch, C. Losem, A. Matzdorff, C. Balser, K. Schalk, D. Kofahl-Krause, U. Kaiser, W. Knauf, A. Banat, D. Hoelzer, W. Brugger, on behalf of the StiL
Journal: Blood
Blood (2007) 110 (11): 385.
https://doi.org/10.1182/blood.V110.11.385.385
Published: 2007